Diffuse Large B-Cell Lymphoma Unclassifiable

Diffuse Large B-Cell Lymphoma Unclassifiable — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 6
Ph III recruiting: 0
Growth YoY: —
Industry share: 18%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–1 of 1 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03742258	Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma	completed	Phase 1	12	Northwestern UniversityOTHER	1	Jun 18, 2025	clinicaltrials

Data updated 22 days agoSource updated Jun 18, 2025source: clinicaltrials